---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000488"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:46:53.394931+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139

## Summary
- NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.
- Data show smooth, non-fluctuating in vivo release and continuous semaglutide exposure, supporting potential for once or twice-yearly dosing.
- Vivani's proprietary NanoPortal technology demonstrated versatility beyond exenatide implant NPM-115, with in vitro stability over one year.
- First-in-human study LIBERATE-1 for NPM-115 remains on track for top-line data by mid-2025, providing critical information for NPM-139.

## SEC filing metadata
- accession: 0001753926-25-000488
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000488/0001753926-25-000488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000488/vani-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000488
- JSON: https://secwatch.observer/filing/0001753926-25-000488.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.